This page describes pharmacological agents that may have legal restrictions, side effects, and drug interactions in your jurisdiction. Information is for educational research only — consult a clinician before considering any compound.

Low-dose naltrexone

1.5-4.5 mg naltrexone (vs standard 50 mg).

Aliases (4)

LDN · ULDN ultra-low-dose naltrexone · 1.5 mg naltrexone · 4.5 mg naltrexone

TYPICAL DOSE

—

ROUTE

—

CYCLE

—

STORAGE

—

Overview

What is Low-dose naltrexone?

1.5-4.5 mg naltrexone (vs standard 50 mg). TLR4 antagonism + endogenous opioid rebound mechanism. Real signal in fibromyalgia + Crohn's + MS. Cheap, low-risk, requires compounding pharmacy. OPTIONAL-ADD if autoimmune/chronic pain ever indicated.

What to Expect

Week 1
Tolerability and dose-response.
Week 2-4
Early effect window.
Week 4-8
Peak benefit assessment.
Week 8+
Cycle decision point.

Was this helpful?

Your feedback shapes what we research deeper.

How was your experience with this compound?

Anonymous · one vote per session · results below at 5+ votes.

Loading…

✎

See something off?

Most of this wiki is AI-generated. Suggest a correction, dosing update, or new evidence — we review every submission.

Discussion — click to load ▸

Loading…

Continue: Extended research →

Our verdict, decision matrix, deep dives, controversies, sources

Related compounds

Cross-referenced from Low-dose naltrexone

Naltrexone (Standard-dose + Low-Dose / LDN)

Opioid receptor antagonist (mu/kappa/delta) — DOSE-DEPENDENT mechanism splits cleanly into two compounds

Atypical psychedelic / oneirogen (West African iboga shrub alkaloid). Long-acting, dissociative-adjacent, primarily used in non-medical opioid + stimulant detox contexts.

Arylcyclohexylamine dissociative anesthetic / non-competitive open-channel NMDA receptor antagonist with sigma-1 agonism, opioid (μ/κ/δ) low-affinity binding, and downstream glutamate-burst → AMPA → BDNF → mTORC1 plasticity cascade